Biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) will be reporting results tomorrow afternoon. Here’s what you need to know.

BioMarin Pharmaceutical beat analysts’ revenue expectations by 5.5% last quarter, reporting revenues of $745.7 million, up 28.3% year on year. It was a very strong quarter for the company, with a solid beat of analysts’ full-year EPS guidance estimates and an impressive beat of analysts’ EPS estimates.

Is BioMarin Pharmaceutical a buy or sell going into earnings? Read our full analysis here, it’s free.

This quarter, analysts are expecting BioMarin Pharmaceutical’s revenue to grow 10.4% year on year to $713.2 million, slowing from the 20.2% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.74 per share.

Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. BioMarin Pharmaceutical has missed Wall Street’s revenue estimates three times over the last two years.

Looking at BioMarin Pharmaceutical’s peers in the therapeutics segment, some have already reported their Q4 results, giving us a hint as to what we can expect. Gilead Sciences delivered year-on-year revenue growth of 6.4%, beating analysts’ expectations by 6.3%, and AbbVie reported revenues up 5.6%, topping estimates by 1.9%. Gilead Sciences traded up 7.5% following the results while AbbVie was also up 8.3%.

Read our full analysis of Gilead Sciences’s results here and AbbVie’s results here.

Stocks generally had a good 2024. The Fed fought high inflation and won without sending the economy into a recession, otherwise lovingly known as a soft landing. The US Central Band is now cutting rates. That, plus the election of Donald Trump in November 2024, sent markets even higher, and while some of the therapeutics stocks have shown solid performance, the group has generally underperformed, with share prices down 2.4% on average over the last month. BioMarin Pharmaceutical is up 4.2% during the same time and is heading into earnings with an average analyst price target of $96.86 (compared to the current share price of $65.13).

Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we’ve identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link.